← Browse by Condition
Medical Condition

rectal adenocarcinoma

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for rectal adenocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — rectal adenocarcinoma Clinical Trials

How many clinical trials are currently recruiting for rectal adenocarcinoma?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for rectal adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for rectal adenocarcinoma?
rectal adenocarcinoma research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a rectal adenocarcinoma clinical trial?
Eligibility criteria for rectal adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
Istanbul University 1 trial
University Hospital, Antwerp 1 trial
M.D. Anderson Cancer Center 1 trial
Guardant Health, Inc. 1 trial
Sir Run Run Shaw Hospital 1 trial

Recruiting Clinical Trials

NCT07802197
Recruiting
Neoadjuvant Radiotherapy vs Upfront Surgery in Locally Advanced Proximal Rectal Cancer
Enrollment
100 pts
Location
Turkey (Türkiye)
Sponsor
Istanbul University
View Trial →
NCT07339904
Recruiting
ProLARS Trial: Prospective Longitudinal Follow-up of Low Anterior Resection Syndrome (LARS) and COREFO Score After Rectum Surgery in Patients Undergoing Upfront Surgery or Different Neo-adjuvant Treatment Regimens
Enrollment
100 pts
Location
Belgium
Sponsor
University Hospital, Antwerp
View Trial →
NCT02107105
Recruiting
Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer
Enrollment
430 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT05059444
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Enrollment
2,020 pts
Location
United States, Franc...
Sponsor
Guardant Health, Inc.
View Trial →
NCT06266832 Phase 2
Recruiting
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma
Enrollment
30 pts
Location
China
Sponsor
Sir Run Run Shaw Hospital
View Trial →

Related Conditions

lars low anterior resection syndrome (1) rectal resection (1) low anterior resection (1) total mesorectal excision (1) stage i rectal cancer ajcc v8 (1) stage ii rectal cancer ajcc v8 (1) stage iia rectal cancer ajcc v8 (1) stage iib rectal cancer ajcc v8 (1) stage iic rectal cancer ajcc v8 (1) stage iii rectal cancer ajcc v8 (1) stage iiia rectal cancer ajcc v8 (1) stage iiib rectal cancer ajcc v8 (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology